Clinical Trials Browser

Phase 1 × trametinib × Tumor-Agnostic × Clear all

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT02070549 2025-02-13

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Phase 1 Completed

Neoplasm Metastasis

NCT01231594 2019-03-22

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Phase 1 Completed

Neoplasms

NCT02939846 2018-09-14

Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

Phase 1 Withdrawn

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

Neoplasms

NCT01371487 2017-11-13

GSK1120212 Food-effect Study

Phase 1 Completed

Neoplasms

NCT01387204 2017-11-13

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

Phase 1 Completed

Neoplasms

NCT01416337 2017-11-13

Absolute Bioavialability of GSK1120212

Phase 1 Completed

Neoplasms

NCT01248858 2017-05-09

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

Phase 1 Terminated

Neoplasms

NCT02292732 2016-01-26

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

Phase 1 Withdrawn

Neoplasms